Management of antipsychotic-related weight gain

References

• Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. (Millwood)28(5), w822–w831 (2009).
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr. Res.66(1), 51–57 (2004).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr. Serv.54(4), 565–567 (2003).
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs19(Suppl. 1), 1–93 (2005).
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry156(11), 1686–1696 (1999).
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet373(9657), 31–41 (2009).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry65(2), 267–272 (2004).
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J. Clin. Psychopharmacol.25(3), 255–258 (2005).
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet371(9618), 1085–1097 (2008).
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Perkins DO et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry164(7), 1050–1060 (2007).
   PubMed Web of Science ®Google Scholar
• Ratzoni G, Gothelf D, Brand-Gothelf A et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J. Am. Acad. Child Adolesc. Psychiatry41(3), 337–343 (2002).
   PubMed Web of Science ®Google Scholar
• Sikich L, Frazier JA, McClellan J et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am. J. Psychiatry165(11), 1420–1431 (2008).
   PubMed Web of Science ®Google Scholar
• McClellan J, Sikich L, Findling RL et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J. Am. Acad. Child Adolesc. Psychiatry46(8), 969–978 (2007).
   PubMed Web of Science ®Google Scholar
• Safer DJ. A comparison of risperidone-induced weight gain across the age span. J. Clin. Psychopharmacol.24(4), 429–436 (2004).
   PubMed Web of Science ®Google Scholar
• Maayan L, Vakhrusheva J, Sheridan EM, Correll CU. Risperidone across the age span: a meta-analytic comparison of placebo-controlled trials. Presented at: New Clinical Drug Evaluation Unit Meeting. Boca Raton, FL, USA, 14–17 June 2010.
   Google Scholar
• Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J. Clin. Psychiatry62(4), 231–238 (2001).
   PubMed Web of Science ®Google Scholar
• Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J. Psychiatr. Res.43(6), 620–626 (2009).
   PubMed Web of Science ®Google Scholar
• Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR, Chang WH. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J. Clin. Psychiatry64(3), 316–320 (2003).
   PubMed Web of Science ®Google Scholar
• Lane HY, Liu YC, Huang CL et al. Risperidone-related weight gain: genetic and nongenetic predictors. J. Clin. Psychopharmacol.26(2), 128–134 (2006).
   PubMed Web of Science ®Google Scholar
• Wetterling T, Mussigbrodt HE. Weight gain: side effect of atypical neuroleptics? J. Clin. Psychopharmacol.19(4), 316–321 (1999).
   PubMed Web of Science ®Google Scholar
• Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J. Child Adolesc. Psychopharmacol.19(2), 101–109 (2009).
   PubMed Web of Science ®Google Scholar
• Neovius M, Eberhard J, Lindstrom E, Levander S. Weight development in patients treated with risperidone: a 5-year naturalistic study. Acta Psychiatr. Scand.115(4), 277–285 (2007).
   PubMed Web of Science ®Google Scholar
• Weiss M, Panagiotopoulos C, Giles L et al. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J. Child Adolesc. Psychopharmacol.19(5), 575–582 (2009).
   PubMed Web of Science ®Google Scholar
• Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J. Am. Acad. Child Adolesc. Psychiatry46(6), 687–700 (2007).
   PubMed Web of Science ®Google Scholar
• Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr. Res.93(1–3), 90–98 (2007).
   PubMed Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA302(16), 1765–1773 (2009).
   PubMed Web of Science ®Google Scholar
• Gentile S. Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes. Rev.10(5), 527–542 (2009).
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr., Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J. Clin. Psychiatry68(10), 1480–1491 (2007).
   PubMed Web of Science ®Google Scholar
• Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur. Neuropsychopharmacol.5(4), 437–440 (1995).
   PubMed Web of Science ®Google Scholar
• Lee E, Leung CM, Wong E. Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. J. Clin. Psychiatry65(6), 864–866 (2004).
   PubMed Web of Science ®Google Scholar
• Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia – a randomized double-blind controlled, short-term prospective study. Schizophr. Res.101(1–3), 266–272 (2008).
   PubMed Web of Science ®Google Scholar
• Allison DB, Loebel AD, Lombardo I, Romano SJ, Siu CO. Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? Psychiatry Res.170(2–3), 172–176 (2009).
   PubMed Web of Science ®Google Scholar
• Lipkovich I, Jacobson JG, Hardy TA, Hoffmann VP. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry8, 78 (2008).
   PubMedGoogle Scholar
• Stauffer VL, Lipkovich I, Hoffmann VP, Heinloth AN, McGregor HS, Kinon BJ. Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents: a post-hoc analysis. BMC Psychiatry9, 12 (2009).
   PubMedGoogle Scholar
• Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ. Weight gain during treatment of bipolar I patients with olanzapine. J. Clin. Psychiatry65(12), 1679–1687 (2004).
   PubMed Web of Science ®Google Scholar
• Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J. Clin. Psychiatry70(7), 1041–1050 (2009).
   PubMed Web of Science ®Google Scholar
• Reaven GM, Lieberman JA, Sethuraman G et al. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. J. Psychiatr. Res.43(11), 997–1002 (2009).
   PubMed Web of Science ®Google Scholar
• Ader M, Garvey WT, Phillips LS et al. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. J. Psychiatr. Res.42(13), 1076–1085 (2008).
   PubMed Web of Science ®Google Scholar
• Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology32(2), 289–297 (2007).
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet1(8636), 495 (1989).
   PubMed Web of Science ®Google Scholar
• Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can. J. Psychiatry51(6), 382–386 (2006).
   PubMed Web of Science ®Google Scholar
• Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry160(2), 284–289 (2003).
   PubMed Web of Science ®Google Scholar
• Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med.24(5), 481–485 (2007).
   PubMed Web of Science ®Google Scholar
• Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. J. Clin. Psychiatry70(7), 997–1000 (2009).
   PubMed Web of Science ®Google Scholar
• Fernandez-Egea E, Bernardo M, Donner T et al. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br. J. Psychiatry194(5), 434–438 (2009).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr. Scand.119(1), 4–14 (2009).
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res.80(1), 19–32 (2005).
   PubMed Web of Science ®Google Scholar
• De Hert M, van Winkel R, Van Eyck D et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin. Pract. Epidemiol. Ment. Health2, 14 (2006).
   PubMedGoogle Scholar
• Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care24(4), 683–689 (2001).
   PubMed Web of Science ®Google Scholar
• Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chronic Dis.3(2), A42 (2006).
   PubMedGoogle Scholar
• Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br. J. Psychiatry196(2), 116–121 (2010).
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Lonnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet374(9690), 620–627 (2009).
   PubMed Web of Science ®Google Scholar
• De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr. Res.117(1), 68–74 (2009).
   Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry64(10), 1123–1131 (2007).
   PubMed Web of Science ®Google Scholar
• Arjona AA, Zhang SX, Adamson B, Wurtman RJ. An animal model of antipsychotic-induced weight gain. Behav. Brain Res.152(1), 121–127 (2004).
   PubMed Web of Science ®Google Scholar
• Gothelf D, Falk B, Singer P et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am. J. Psychiatry159(6), 1055–1057 (2002).
   PubMed Web of Science ®Google Scholar
• Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am. J. Psychiatry162(1), 118–123 (2005).
   PubMed Web of Science ®Google Scholar
• Zurlo F, Lillioja S, Esposito-Del Puente A et al. Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. Am. J. Physiol.259(5 Pt 1), E650–E657 (1990).
   PubMed Web of Science ®Google Scholar
• Sharpe JK, Stedman TJ, Byrne NM, Wishart C, Hills AP. Energy expenditure and physical activity in clozapine use: implications for weight management. Aust. N Z J. Psychiatry40(9), 810–814 (2006).
   PubMed Web of Science ®Google Scholar
• Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl.)174(4), 477–489 (2004).
   PubMed Web of Science ®Google Scholar
• Sentissi O, Viala A, Bourdel MC et al. Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients. Int. Clin. Psychopharmacol.24(5), 257–264 (2009).
   PubMed Web of Science ®Google Scholar
• Ota M, Mori K, Nakashima A et al. Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. Clin. Exp. Pharmacol. Physiol.29(11), 980–989 (2002).
   PubMed Web of Science ®Google Scholar
• Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology29(1), 133–145 (2004).
   PubMed Web of Science ®Google Scholar
• Woods SW, Martin A, Spector SG, McGlashan TH. Effects of development on olanzapine-associated adverse events. J. Am. Acad. Child Adolesc. Psychiatry41(12), 1439–1446 (2002).
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW, Fucetola R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry59(4), 337–345 (2002).
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Copeland PM et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch. Gen. Psychiatry62(1), 19–28 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson DE, Yamazaki H, Ward KM et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes54(5), 1552–1558 (2005).
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms. Pharmacol. Ther.125(1), 169–179 (2010).
   PubMed Web of Science ®Google Scholar
• Bai YM, Chen TT, Yang WS et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr. Res.111(1–3), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB. The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J. Clin. Endocrinol. Metab.91(2), 718–721 (2006).
   PubMed Web of Science ®Google Scholar
• Maayan LA, Vakhrusheva J. Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. Hum. Psychopharmacol.25(2), 133–138 (2010).
   PubMed Web of Science ®Google Scholar
• Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology30(1), 184–191 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br. J. Psychiatry184, 58–62 (2004).
   PubMed Web of Science ®Google Scholar
• Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog. Neuropsychopharmacol. Biol. Psychiatry34(1), 1–4 (2010).
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology28(3), 519–526 (2003).
   PubMed Web of Science ®Google Scholar
• Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Natl Acad. Sci. USA104(9), 3456–3459 (2007).
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry29(6), 1021–1028 (2005).
   PubMed Web of Science ®Google Scholar
• Mulder H, Franke B, van der-Beek van der AA et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J.7(5), 318–324 (2007).
   PubMed Web of Science ®Google Scholar
• De Luca V, Muller DJ, Hwang R et al. HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Hum. Psychopharmacol.22(7), 463–467 (2007).
   PubMed Web of Science ®Google Scholar
• Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet. Genomics15(4), 195–200 (2005).
   PubMedGoogle Scholar
• Souza RP, De Luca V, Muscettola G et al. Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry32(8), 1848–1853 (2008).
   PubMed Web of Science ®Google Scholar
• Siffert W, Forster P, Jockel KH et al. Worldwide ethnic distribution of the G protein b3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J. Am. Soc. Nephrol.10(9), 1921–1930 (1999).
   PubMed Web of Science ®Google Scholar
• Lencz T, Malhotra AK. Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin. Neurosci.11(4), 405–415 (2009).
   PubMedGoogle Scholar
• Tiwari AK, Zai CC, Likhodi O et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology35(6), 1315–1324 (2010).
   PubMed Web of Science ®Google Scholar
• Liu YR, Loh EW, Lan TH et al. ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J.10(1), 30–39 (2010).
   PubMed Web of Science ®Google Scholar
• Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J. Clin. Psychiatry69(Suppl. 1), 4–17 (2008).
   Web of Science ®Google Scholar
• Pae CU, Serretti A, Chiesa A et al. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur. Neuropsychopharmacol.19(8), 562–570 (2009).
   PubMed Web of Science ®Google Scholar
• Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med.6, 17 (2008).
   PubMedGoogle Scholar
• Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am. J. Psychiatry163(12), 2090–2095 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Davis S, Covell N et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr. Res.107(1), 22–29 (2009).
   PubMed Web of Science ®Google Scholar
• De Hert M, Hanssens L, van Winkel R et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr. Bull.33(3), 823–830 (2007).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Davis VG, Goff DC et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr. Res.101(1–3), 273–286 (2008).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin. Ther.27(12), 1930–1941 (2005).
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Campos JA, Marcus RN et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J. Clin. Psychiatry69(7), 1046–1056 (2008).
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Meyer JM, Baker RA et al. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophr. Res.106(2–3), 300–307 (2008).
   PubMed Web of Science ®Google Scholar
• Lin CC, Bai YM, Wang YC et al. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics. J. Clin. Psychopharmacol.29(6), 529–536 (2009).
   PubMed Web of Science ®Google Scholar
• Ried LD, Brumback B, Bengtson MA, Garman PM, Hsu C, McConkey JR. Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics. J. Am. Pharm. Assoc.49(2), 223–231 (2009).
   Google Scholar
• Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology33(5), 985–994 (2008).
   PubMed Web of Science ®Google Scholar
• Casey DE, Carson WH, Saha AR et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl.)166(4), 391–399 (2003).
   PubMed Web of Science ®Google Scholar
• Montes JM, Rodriguez JL, Balbo E et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog. Neuropsychopharmacol. Biol. Psychiatry31(2), 383–388 (2007).
   PubMed Web of Science ®Google Scholar
• Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br. J. Psychiatry193(2), 101–107 (2008).
   PubMed Web of Science ®Google Scholar
• Gabriele JM, Dubbert PM, Reeves RR. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. Obes. Rev.10(4), 442–455 (2009).
   PubMed Web of Science ®Google Scholar
• Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J. Clin. Psychiatry67(8), 1253–1260 (2006).
   PubMed Web of Science ®Google Scholar
• Kalarchian MA, Levine MD, Arslanian SA et al. Family-based treatment of severe pediatric obesity: randomized, controlled trial. Pediatrics124(4), 1060–1068 (2009).
   PubMed Web of Science ®Google Scholar
• Epstein LH, Valoski A, Wing RR, McCurley J. Ten-year follow-up of behavioral, family-based treatment for obese children. JAMA264(19), 2519–2523 (1990).
   PubMed Web of Science ®Google Scholar
• Johnston CA, Steele RG. Treatment of pediatric overweight: an examination of feasibility and effectiveness in an applied clinical setting. J. Pediatr. Psychol.32(1), 106–110 (2007).
   PubMed Web of Science ®Google Scholar
• Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry45(7), 771–791 (2006).
   PubMed Web of Science ®Google Scholar
• Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Schizophr. Bull.33(3), 654–656 (2007).
   PubMed Web of Science ®Google Scholar
• Baptista T, ElFakih Y, Uzcategui E et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs22(6), 477–495 (2008).
   PubMed Web of Science ®Google Scholar
• Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology35(7), 1520–1530 (2010).
   PubMed Web of Science ®Google Scholar
• Baptista T, Martinez J, Lacruz A et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can. J. Psychiatry51(3), 192–196 (2006).
   PubMed Web of Science ®Google Scholar
• Baptista T, Rangel N, Fernandez V et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr. Res.93(1–3), 99–108 (2007).
   PubMed Web of Science ®Google Scholar
• Carrizo E, Fernandez V, Connell L et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr. Res.113(1), 19–26 (2009).
   PubMed Web of Science ®Google Scholar
• Wu RR, Zhao JP, Guo XF et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am. J. Psychiatry165(3), 352–358 (2008).
   PubMed Web of Science ®Google Scholar
• Wu RR, Zhao JP, Jin H et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA299(2), 185–193 (2008).
   PubMed Web of Science ®Google Scholar
• Arman S, Sadramely MR, Nadi M, Koleini N. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med. J.29(8), 1130–1134 (2008).
   PubMed Web of Science ®Google Scholar
• Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am. J. Psychiatry163(12), 2072–2079 (2006).
   PubMed Web of Science ®Google Scholar
• Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr. Scand.117(6), 412–419 (2008).
   PubMed Web of Science ®Google Scholar
• Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann. Intern. Med.137(1), 25–33 (2002).
   PubMed Web of Science ®Google Scholar
• Canitano R. Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev.27(3), 228–232 (2005).
   PubMed Web of Science ®Google Scholar
• Roerig JL, Steffen KJ, Mitchell JE, Crosby RD, Gosnell BA. An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects. Biol. Psychiatry65(7), 607–613 (2009).
   PubMed Web of Science ®Google Scholar
• Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv. Ther.26(10), 959–969 (2009).
   PubMed Web of Science ®Google Scholar
• Gross C, Blasey CM, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring) DOI: 10.1038/oby.2010.51 (2010) (Epub ahead of print).
   Google Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA295(7), 761–775 (2006).
   PubMed Web of Science ®Google Scholar
• Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care31(9), 1816–1823 (2008).
   PubMed Web of Science ®Google Scholar
• Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet372(9653), 1906–1913 (2008).
   PubMed Web of Science ®Google Scholar
• Roth JD, Roland BL, Cole RL et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl Acad. Sci. USA105(20), 7257–7262 (2008).
   PubMed Web of Science ®Google Scholar
• Chakrabarti R. Pharmacotherapy of obesity: emerging drugs and targets. Expert Opin. Ther. Targets13(2), 195–207 (2009).
   PubMed Web of Science ®Google Scholar
• Baptista T, Uzcategui E, Rangel N et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res.159(1–2), 250–253 (2008).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry65(2), 267–272 (2004).
   PubMed Web of Science ®Google Scholar
• Barnes TR, Paton C, Cavanagh MR, Hancock E, Taylor DM. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr. Bull.33(6), 1397–1403 (2007).
   PubMed Web of Science ®Google Scholar
• Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am. J. Psychiatry166(3), 345–353 (2009).
   PubMed Web of Science ®Google Scholar
• Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J. Clin. Psychopharmacol.29(1), 26–32 (2009).
   PubMed Web of Science ®Google Scholar
• Morrato EH, Druss B, Hartung DM et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch. Gen. Psychiatry67(1), 17–24 (2010).
   PubMed Web of Science ®Google Scholar
• Morrato EH, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J. Clin. Psychiatry69(2), 316–322 (2008).
   PubMed Web of Science ®Google Scholar
• Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care32(6), 1037–1042 (2009).
   PubMed Web of Science ®Google Scholar
• Morrato EH, Nicol GE, Maahs D et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch. Pediatr. Adolesc. Med.164(4), 344–351 (2010).
   PubMed Web of Science ®Google Scholar
• Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl.)205(1), 171–174 (2009).
   PubMed Web of Science ®Google Scholar
• Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry66(2), 205–212 (2005).
   PubMed Web of Science ®Google Scholar
• Khazaal Y, Fresard E, Rabia S et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr. Res.91(1–3), 169–177 (2007).
   PubMed Web of Science ®Google Scholar
• Kwon JS, Choi JS, Bahk WM et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J. Clin. Psychiatry67(4), 547–553 (2006).
   PubMed Web of Science ®Google Scholar
• McKibbin CL, Patterson TL, Norman G et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr. Res.86(1–3), 36–44 (2006).
   PubMed Web of Science ®Google Scholar
• Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr. Res.83(1), 95–101 (2006).
   PubMed Web of Science ®Google Scholar
• Poulin MJ, Chaput JP, Simard V et al. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust. N Z J. Psychiatry41(12), 980–989 (2007).
   PubMed Web of Science ®Google Scholar
• Milano W, Grillo F, Del Mastro A et al. Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study. Adv. Ther.24(1), 123–134 (2007).
   PubMed Web of Science ®Google Scholar
• Wu MK, Wang CK, Bai YM, Huang CY, Lee SD. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr. Serv.58(4), 544–550 (2007).
   PubMed Web of Science ®Google Scholar
• Mauri M, Simoncini M, Castrogiovanni S et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry41(1), 17–23 (2008).
   PubMed Web of Science ®Google Scholar
• Scocco P, Longo R, Caon F. Weight change in treatment with olanzapine and a psychoeducational approach. Eat. Behav.7(2), 115–124 (2006).
   PubMedGoogle Scholar
• Alvarez-Jimenez M, Martinez-Garcia O, Perez-Iglesias R, Ramirez ML, Vazquez-Barquero JL, Crespo-Facorro B. Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr. Res.116(1), 16–19 (2010).
   PubMed Web of Science ®Google Scholar
• Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust. N Z J. Psychiatry39(6), 479–486 (2005).
   PubMed Web of Science ®Google Scholar
• Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. J. Nurs. Scholarsh.35(3), 237–241 (2003).
   PubMed Web of Science ®Google Scholar
• Deberdt W, Winokur A, Cavazzoni PA et al. Amantadine for weight gain associated with olanzapine treatment. Eur. Neuropsychopharmacol.15(1), 13–21 (2005).
   PubMed Web of Science ®Google Scholar
• Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am. J. Psychiatry162(9), 1744–1746 (2005).
   PubMed Web of Science ®Google Scholar
• Modell W, Hussar AE. Failure of dextroamphetamine sulfate to influence eating and sleeping patterns in obese schizophrenic patients: clinical and pharmacological significance. JAMA193, 275–278 (1965).
   PubMed Web of Science ®Google Scholar
• Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. A clinical trial of the efficacy and acceptability of d-fenfluramine in the treatment of neuroleptic-induced obesity. Br. J. Psychiatry153, 208–213 (1988).
   PubMed Web of Science ®Google Scholar
• Bustillo JR, Lauriello J, Parker K et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology28(3), 527–529 (2003).
   PubMed Web of Science ®Google Scholar
• Assuncao SS, Ruschel SI, Rosa Lde C et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev. Bras. Psiquiatr.28(4), 270–276 (2006).
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum. Psychopharmacol.18(6), 457–461 (2003).
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum. Psychopharmacol.19(1), 37–40 (2004).
   PubMed Web of Science ®Google Scholar
• Joffe G, Takala P, Tchoukhine E et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry69(5), 706–711 (2008).
   PubMed Web of Science ®Google Scholar
• Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J. Clin. Psychiatry63(4), 345–348 (2002).
   PubMed Web of Science ®Google Scholar
• Baptista T, Rangel N, El Fakih Y et al. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry42(1), 14–19 (2009).
   PubMed Web of Science ®Google Scholar
• Henderson DC, Fan X, Sharma B et al. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr. Scand.119(6), 457–465 (2009).
   PubMed Web of Science ®Google Scholar
• Henderson DC, Copeland PM, Daley TB et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am. J. Psychiatry162(5), 954–962 (2005).
   PubMed Web of Science ®Google Scholar
• Henderson DC, Fan X, Copeland PM et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr. Scand.115(2), 101–105 (2007).
   PubMed Web of Science ®Google Scholar
• Afshar H, Roohafza H, Mousavi G et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J. Psychopharmacol.23(2), 157–162 (2009).
   PubMed Web of Science ®Google Scholar
• Roy Chengappa K, Kupfer DJ, Parepally H et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord.9(6), 609–617 (2007).
   PubMed Web of Science ®Google Scholar
• Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin. Neuropharmacol.28(4), 169–175 (2005).
   PubMed Web of Science ®Google Scholar
• Narula PK, Rehan HS, Unni KE, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr. Res.118(1–3), 218–223 (2010).
   PubMed Web of Science ®Google Scholar
• Nickel MK, Nickel C, Muehlbacher M et al. Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J. Clin. Psychopharmacol.25(3), 211–217 (2005).
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur. Neuropsychopharmacol.14(4), 332–336 (2004).
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Pashinian A, Gil-Ad I et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am. J. Psychiatry159(6), 1058–1060 (2002).
   PubMed Web of Science ®Google Scholar
• Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl.)149(2), 163–169 (2000).
   PubMed Web of Science ®Google Scholar
• Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J. Clin. Psychiatry65(6), 766–771 (2004).
   PubMed Web of Science ®Google Scholar
• Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur. Neuropsychopharmacol.13(2), 81–85 (2003).
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Isaacs I, Fuchs C et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am. J. Psychiatry160(2), 297–302 (2003).
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Fuchs C, Pashinian A et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl.)192(3), 441–448 (2007).
   PubMed Web of Science ®Google Scholar
• Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr. Res.82(1), 115–117 (2006).
   PubMed Web of Science ®Google Scholar
• Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J. Am. Acad. Child Adolesc. Psychiatry47(1), 9–20 (2008).
   PubMed Web of Science ®Google Scholar